Phase II, Open Label, Non-randomized, Trial of BKM120 as Palliative Treatment for Metastatic or Locally Advanced Cervical Cancer After Failure to Platinum Based Regimen
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Buparlisib (Primary)
- Indications Cervical cancer
- Focus Adverse reactions
- Sponsors Novartis
- 03 Feb 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 12 Jan 2016 Planned number of patients changed from 27 to 29 as reported by ClinicalTrials.gov.
- 12 Jan 2016 Planned initiation date changed from 1 Nov 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov.